Carrick Therapeutics was launched in 2016 with the aim of building the leading European based oncology company with a world class innovative R&D pipeline focusing on targeting key pathways in cancer progression and adaptive resistance.


Carrick Therapeutics’ Board of Directors combines expertise from the pharmaceutical industry and the investment community with the shared goal of improving the lives of cancer patients.


Carrick Therapeutics is collaborating with world-class cancer researchers from Cambridge, Oxford, London, and Ireland to defeat cancer.

Sir John Bell
Chairman of Scientific Advisory Board, Carrick Therapeutics
University of Oxford

Professor Chas Bountra
University of Oxford

Professor Johann DeBono
Royal Marsden Hospital

Professor William Gallagher
University College Dublin

Professor Steve Jackson
University of Cambridge

Professor Peter Johnson
University of Southampton

Professor David Kerr
University of Oxford

Professor Michael O’Dwyer
National University of Ireland (Galway)

Doctor Anthony Quinn

Professor John Robertson
University of Nottingham

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.